All In Biotech

Investigational drug · Phase 3

Ecopipam Hydrochloride

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Tourette Syndrome, Tourette Disorder.

Phase 3

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

1 still active

All registered trials

13

Any phase or sponsor naming "Ecopipam Hydrochloride"

First trial start

2023

Jan 31, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Ecopipam Hydrochloride", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Tourette Syndrome
  • Tourette Disorder

Approved drugs for the same conditions: Rare and genetic disease

Largest trials

Live from ClinicalTrials.gov: studies naming "Ecopipam Hydrochloride" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Tourette Syndrome

  • SCI-110Phase 21 trial

    Neurothera Labs Inc. · Tourette Syndrome

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.